DCM
CORT icon

DGS Capital Management’s Corcept Therapeutics CORT Stock Holding History

DGS Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,217
Closed -$350K – 553
2025
Q3 		$350K Sell
4,217
-768
-15% -$55.6K 0.06% 247
2025
Q2 		$366K Buy
4,985
+797
+19% +$57.8K 0.08% 207
2025
Q1 		$478K Buy
+4,188
New +$255K 0.13% 165

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DGS Capital Management's CORT Position: Q4 2025 in Review

DGS Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 4,217 shares — an estimated $350K sold.

DGS Capital Management first reported a position in CORT in Q1 2025 and held it in 3 quarters. The position peaked at $478K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • DGS Capital Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • DGS Capital Management sold 4,217 Corcept Therapeutics shares in Q4 2025, an estimated $350K.
  • DGS Capital Management first reported a position in Corcept Therapeutics in Q1 2025 and held it in 3 quarters.
  • DGS Capital Management's Corcept Therapeutics position peaked at $478K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on DGS Capital Management's 13F filing for Q4 2025, filed 24 Feb 2026.